IFC & Insurance Marketing’s Moderna MRNA Stock Holding History

IFC & Insurance Marketing’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-100	Closed	-$3K	–	460
2025 Q4	$3K	Buy	+100	New	+$2.72K	﹤0.01%	601

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

IFC & Insurance Marketing's MRNA Position: Q1 2026 in Review

IFC & Insurance Marketing sold out of Moderna (MRNA) in Q1 2026, closing a stake of 100 shares — an estimated $3K sold.

IFC & Insurance Marketing first reported a position in MRNA in Q4 2025 and held it in 1 quarter. The position peaked at $3K in Q4 2025. 726 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

IFC & Insurance Marketing reported no remaining Moderna position as of Q1 2026 after selling out during the quarter.
IFC & Insurance Marketing sold 100 Moderna shares in Q1 2026, an estimated $3K.
IFC & Insurance Marketing first reported a position in Moderna in Q4 2025 and held it in 1 quarter.
IFC & Insurance Marketing's Moderna position peaked at $3K in Q4 2025.
726 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on IFC & Insurance Marketing's 13F filing for Q1 2026, filed 17 Apr 2026.